Short Interest in VanEck Biotech ETF (NASDAQ:BBH) Decreases By 96.4%

VanEck Biotech ETF (NASDAQ:BBH) saw a significant decrease in short interest during the month of December. As of December 15th, there was short interest totalling 800 shares, a decrease of 96.4% from the November 30th total of 22,500 shares. Based on an average daily volume of 7,800 shares, the short-interest ratio is presently 0.1 days.

Institutional Trading of VanEck Biotech ETF

A number of large investors have recently made changes to their positions in BBH. Truvestments Capital LLC acquired a new stake in shares of VanEck Biotech ETF during the third quarter worth $44,000. FSA Wealth Management LLC acquired a new stake in VanEck Biotech ETF in the 3rd quarter worth about $54,000. Coastline Trust Co purchased a new stake in VanEck Biotech ETF in the 3rd quarter valued at about $59,000. Wilmington Savings Fund Society FSB acquired a new position in shares of VanEck Biotech ETF during the 3rd quarter valued at about $166,000. Finally, Tyler Stone Wealth Management increased its stake in shares of VanEck Biotech ETF by 79.5% during the 3rd quarter. Tyler Stone Wealth Management now owns 1,472 shares of the company’s stock valued at $261,000 after acquiring an additional 652 shares during the last quarter. Institutional investors and hedge funds own 32.05% of the company’s stock.

VanEck Biotech ETF Trading Down 0.2 %

Shares of BBH traded down $0.28 during mid-day trading on Thursday, reaching $158.68. 8,887 shares of the company’s stock were exchanged, compared to its average volume of 7,306. VanEck Biotech ETF has a 52-week low of $151.35 and a 52-week high of $183.64. The company has a 50-day simple moving average of $166.96 and a two-hundred day simple moving average of $172.63.

VanEck Biotech ETF Announces Dividend

The business also recently declared a dividend, which was paid on Tuesday, December 24th. Stockholders of record on Monday, December 23rd were issued a $1.2517 dividend. The ex-dividend date of this dividend was Monday, December 23rd.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.